Last updated: April 24, 2026
Bicalutamide is an orally administered non-steroidal androgen receptor antagonist used in prostate cancer. Supplier landscapes for bicalutamide break into two practical buckets: API producers (bicalutamide substance) and finished-dose manufacturers (tablets), often under multiple country-specific marketing authorizations.
Who supplies bicalutamide API?
The bicalutamide API supplier set is concentrated in large chemical and generic-API manufacturers that can handle heteroaromatic synthesis, crystallization control, and impurity management for an oncology API. In practice, finished-dose manufacturers source bicalutamide API from one of two channels: (1) vertically integrated chemical firms that also supply intermediates and (2) specialized API producers with consistent batch quality packages.
Common supplier archetypes in bicalutamide supply
- Bulk API producers supplying bicalutamide substance to generic and brand manufacturers under CDMO or direct API contracts.
- Integrated chemical manufacturers that control early-stage intermediates and crystallization to meet impurity limits and polymorph specifications.
What matters in API selection for bicalutamide
- Impurity profile compliance (set by pharmacopeia and marketing authorization specifications)
- Polymorph and crystal form control (to maintain dissolution and bioequivalence)
- Batch-to-batch consistency with validated manufacturing and change control
Which finished-dose manufacturers sell bicalutamide tablets?
Finished-dose supply is broader than API supply because multiple generic tablet makers sell under local authorizations. The market typically uses the same API from a smaller set of API suppliers, then applies tablet formulation and quality controls to achieve local approval.
Typical finished-dose manufacturing model for bicalutamide
- Tablet makers formulate using bicalutamide API plus controlled excipients.
- They execute local process validation and stability programs to align with regulatory requirements.
- They rely on specific supplier grades (API specifications, analytical methods, and impurity acceptance criteria).
Finished-dose units you will see in procurement
- 10 mg tablets (including “bicalutamide” brand/generic listings)
- 50 mg tablets (including common combination regimens in prostate cancer protocols)
- Country-specific labelers that may use different tablet strengths even when the API is the same
How to map bicalutamide suppliers for procurement and due diligence
To treat “suppliers” as a decision asset, procurement teams should map bicalutamide supply across three layers: regulatory authorization, quality capability, and capacity continuity.
1) Regulatory and quality eligibility
- Use the supplier’s DMF or equivalent (if used in your target regions) and confirm whether the supplier supports audits and CMC documentation packages.
- Confirm that the supplier can deliver the exact API grade/spec used by your chosen finished-dose authorization pathway.
2) Analytical package strength
- Confirm the supplier can provide validated HPLC methods and impurity reporting aligned to bicalutamide specifications used in target registrations.
- Verify support for routine stability sample testing and retest dating aligned to your planned shelf life.
3) Capacity and supply continuity
- Oncology APIs often face periodic tightening due to global batch campaigns, crystallization constraints, and long lead times for key intermediates.
- Contract terms should include rolling forecasts, priority allocation, and change notification clauses for process or impurity-method changes.
Supplier selection: what “proof” looks like in bicalutamide documentation
In supplier qualification and vendor management, bicalutamide documentation usually contains:
- CoA with assay and impurity results per release specification
- Confirmation of polymorph/crystal control (where applicable)
- Method descriptions for key impurities and residual solvents
- GMP compliance history and audit outcomes for the manufacturing site(s)
Key Takeaways
- Bicalutamide supply concentrates at the API level among a smaller number of bulk-chemistry producers and expands at the finished-dose level across many tablet manufacturers.
- Procurement should map suppliers by regulatory eligibility, analytical/CMC package strength, and supply continuity controls (forecasting, allocation, change notification).
- The practical question is not “who makes bicalutamide,” but “who can deliver the correct API grade, impurity profile, and crystal/polymorph consistency required by your registration and bioequivalence pathway.”
FAQs
-
What is the typical difference between bicalutamide API suppliers and finished-dose manufacturers?
API suppliers provide bicalutamide substance; finished-dose manufacturers formulate and manufacture tablets under local marketing authorization.
-
Why does polymorph control matter for bicalutamide?
Crystal form affects dissolution behavior and can impact bioequivalence and quality consistency.
-
How do impurity specifications drive supplier qualification for bicalutamide?
Vendors must demonstrate a release and stability profile that matches the regulatory acceptance criteria for impurities and residuals.
-
What contract terms reduce supply disruption risk in bicalutamide?
Rolling forecasts, allocation commitments, change notification, and clear retest/shelf-life terms.
-
Do multiple tablet brands usually rely on the same API source?
Often yes. The same API is commonly used across brands and generics, with differences at the formulation and tablet process stage.
References (APA)
[1] European Medicines Agency. (n.d.). Product information and assessment reports for bicalutamide-containing medicinal products. https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration. (n.d.). Drug product and labeling information for bicalutamide. https://www.fda.gov/
[3] British Pharmacopoeia / USP. (n.d.). Bicalutamide substance specifications and impurity methods. https://www.pharmacopoeia.com/
